Mechanisms of cerebral edema in traumatic brain injury: Therapeutic developments

Current Opinion in Neurology

Volumn 23, Issue 3, 2010, Pages 293-299

  Donkin, James J ^a   Vink, Robert ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aquaporins; Cytotoxic edema; Neurogenic inflammation; Neurotrauma; Neurovascular unit; Trauma; Vasogenic edema

Indexed keywords

AQUAPORIN 1; AQUAPORIN 4; AQUAPORIN 9; BRADYKININ B2 RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; GELATINASE B; MATRIX METALLOPROTEINASE; TACHYKININ; VASOACTIVE AGENT;

BLOOD BRAIN BARRIER; BRAIN EDEMA; DISEASE CLASSIFICATION; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PREDICTION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TRAUMATIC BRAIN INJURY; UPREGULATION;

ANIMALS; AQUAPORINS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN INJURIES; CEREBRAL ARTERIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KININS; RECEPTORS, NEUROKININ-1;

EID: 77951971088     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328337f451     Document Type: Review

References (66)

1. Marmarou A. Pathophysiology of traumatic brain edema: current concepts. Acta Neurochir Suppl 2003; 86:7-10.
2. Feickert HJ, Drommer S, Heyer R. Severe head injury in children: impact of risk factors. J Trauma 1999; 47:33-38. (Pubitemid 29361588)
3. Klatzo I. Pathophysiological aspects of brain edema. Acta Neuropathol (Berl) 1987; 72:236-239.
4. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6:258-268.
5. Nag S, Manias JL, Stewart DJ. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol 2009; 118:197-217.
6. Marmarou A, Takagi H, Shulman K. Biomechanics of brain edema and effects on local cerebral blood flow. Adv Neurol 1980; 28:345-358.
7. Reulen HJ, Graham R, Spatz M, Klatzo I. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg 1977; 46:24-35.
8. Barzo P, Marmarou A, Fatouros P, et al. Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging. J Neurosurg 1997; 87:900-907. (Pubitemid 27508597)
9. Hanstock CC, Faden AI, Bendall MR, Vink R. Diffusion-weighted imaging differentiates ischemic tissue from traumatized tissue. Stroke 1994; 25:843-848.
10. Barzo P, Marmarou A, Fatouros P, et al. Magnetic resonance imaging monitored acute blood-brain barrier changes in experimental traumatic brain injury. J Neurosurg 1996; 85:1113-1121.
11. O'Connor CA, Cernak I, Vink R. The temporal profile of edema formation differs between male and female rats following diffuse traumatic brain injury. Acta Neurochir Suppl 2006; 96:121-124.
12. Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci 2007; 25:231-238.
13. Luh C, Kuhlmann CR, Ackermann B, et al. Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury. J Neurochem 2010; 112:1015-1025.
14. Baskaya MK, Rao AM, Dogan A, et al. The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. Neurosci Lett 1997; 226:33-36.
15. Beaumont A, Marmarou A, Hayasaki K, et al. The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury. Acta Neurochir Suppl 2000; 76:125-129.
16. Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000; 6:159-163.
17. Papadopoulos MC, Verkman AS. Potential utility of aquaporin modulators for therapy of brain disorders. Prog Brain Res 2008; 170:589-601.
18. Taya K, Gulsen S, Okuno K, et al. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta Neurochir Suppl 2008; 102:425-429.
19. Pasantes-Morales H, Cruz-Rangel S. Brain volume regulation: osmolytes and aquaporin perspectives. Neuroscience 2009 [Epub ahead of print].
20. Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 2002; 22:367-378.
21. Aoki K, Uchihara T, Tsuchiya K, et al. Enhanced expression of aquaporin 4 in human brain with infarction. Acta Neuropathol 2003; 106:121-124.
22. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol 2007; 22:778-784.
23. Sorani MD, Zador Z, Hurowitz E, et al. Novel variants in human aquaporin-4 reduce cellular water permeability. Hum Mol Genet 2008; 17:2379-2389.
24. Ding JY, Kreipke CW, Speirs SL, et al. Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury. Neurosci Lett 2009; 453:68-72.
25. Tran N, Kim S, Vincent H, et al. Aquaporin-1-mediated cerebral edema following traumatic brain injury: effects of acidosis and corticosteroid administration. J Neurosurg 2009 [Epub ahead of print].
26. Ghabriel MN, Thomas A, Vink R. Magnesium restores altered aquaporin-4 immunoreactivity following traumatic brain injury to a preinjury state. Acta Neurochir Suppl 2006; 96:402-406.
27. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004; 18:1291-1293.
28. Sun M-C, Honey CR, Berk C, et al. Regulation of aquaporin-4 in a traumatic brain injury model in rats. J Neurosurg 2003; 98:565-569.
29. FazzinaG, Amorini AM, Marmarou C, et al. The PKC activator phorbol myristate acetate decreases brain edema by AQP4 down-regulation following middle cerebral artery occlusion in the rat. J Neurotrauma 2009 [Epub ahead of print].
30. Kikuchi K, Tancharoen S, Matsuda F, et al. Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 2009; 390:1121-1125.
31. Taya K, Marmarou C, Okuno K, et al. Effect of secondary insults upon aquaporin-4 water channels following experimental cortical contusion in rats. J Neurotrauma 2009; 27:229-239.
32. Grossetete M, Phelps J, Arko L, et al. Elevation of matrix met alloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurg 2009; 65:702-708.
33. Hayashi T, Kaneko Y, Yu S, et al. Quantitative analyses of matrix met allopro-teinase activity after traumatic brain injury in adult rats. Brain Res 2009; 1280:172-177.
34. Vajtr D, Benada O, Kukacka J, et al. Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after traumatic brain injury with biochemical markers of BBB leakage and inflammatory response. Physiol Res 2009; 58:263-268.
35. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix met alloproteinases and tissue inhibitors of met alloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009; 158:983-994.
36. Ding JY, Kreipke CW, Schafer P, et al. Synapse loss regulated by matrix met alloproteinases in traumatic brain injury is associated with hypoxia in-ducible factor-1alpha expression. Brain Res 2009; 1268:125-134.
37. Rosenberg GA. Matrix met alloproteinases and their multiple roles in neuro-degenerative diseases. Lancet Neurol 2009; 8:205-216.
38. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix met alloproteinases in cerebral ischemia. Neurosurg Focus 2007; 22:E4.
39. Falo MC, Fillmore HL, Reeves TM, Phillips LL. Matrix met alloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. J Neurosci Res 2006; 84:768-781.
40. Vilalta A, Sahuquillo J, Rosell A, et al. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med 2008; 34:1384-1392.
41. Asahi M, Wang X, Mori T, et al. Effects of matrix met alloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21:7724-7732.
42. Gasche Y, Fujimura M, Morita-Fujimura Y, et al. Early appearance of activated matrix met alloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19:1020-1028. (Pubitemid 30173725)
43. Gidday JM, Gasche YG, Copin JC, et al. Leukocyte-derived matrix met allo-proteinase-9 mediates blood-brain barrier breakdown and isproinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289:H558-H568.
44. Wang X, Jung J, Asahi M, et al. Effects of matrix met alloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000; 20:7037-7042.
45. Fujimoto M, Takagi Y, Aoki T, et al. Tissue inhibitor of met alloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 2008; 28:1674-1685.
46. Homsi S, Federico F, Croci N, et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Research 2009; 1291:122-132.
47. Tejima E, Guo S, Murata Y, et al. Neuroprotective effects of over-expressing tissue inhibitor of met alloproteinaseTIMP-1. J Neurotrauma 2009; 26:1935-1941.
48. Zhao B-Q, Wang S, Kim H-Y, et al. Role of matrix met alloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12:441-445.
49. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 2002; 8:101-105.
50. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000; 20:131-147.
51. Plesnila N, Schulz J, Stoffel M, et al. Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats. J Neurotrauma 2001; 18:1049-1058.
52. Trabold R, Eros C, Zweckberger K, et al. The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010; 30:130-139.
53. Zweckberger K, Plesnila N. Anatibant, a selective nonpeptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett 2009; 454:115-117.
54. Su J, Cui M, Tang Y, et al. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun 2009; 388:205-211.
55. Zausinger S, Lumenta DB, Pruneau D, et al. Therapeutical efficacy of a novel nonpeptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia. Acta Neurochir Suppl 2003; 86:205-207.
56. Ker K, Blackhall K. Beta-2 receptor antagonists for acute traumatic brain injury. Cochrane Database Syst Rev 2008:CD006686.
57. Shakur H, Andrews P, Asser T, et al. The BRAIN TRIAL: a randomised, placebo controlled trial of a bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009; 10:109.
58. Geppetti P, Bertrand C, Ricciardolo FL, Nadel JA. New aspects on the role of kininsinneurogenic inflammation. Can JPhysiol Pharmacol 1995; 73:843-847.
59. Nimmo AJ, Cernak I, Heath DL, et al. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 2004; 38:40-47.
60. Vink R, Young A, Bennett CJ, et al. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir Suppl 2003; 86:257-260.
61. Donkin JJ, Nimmo AJ, Cernak I, et al. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 2009; 29:1388-1398.
62. Donkin JJ, Cernak I, Rodgers KM, Vink R. Mild concussive head injury results in increased brain substance P immunoreactivity. In: Proceedings of the 7th International Neurotrauma Symposium. Medimond International Proceedings; 2004. pp. 75-78.
63. Turner RJ, Blumbergs PC, Sims NR, et al. Increased substance P immuno-reactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl 2006; 96:263-266.
64. Zacest AC, Vink R, Manavis J, et al. Substance P immunoreactivity increases following human traumatic brain injury. Acta Neurochir Suppl 2010; 106:211-216.
65. Brain SD, Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 1985; 86:855-860.
66. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Drug News Perspect 2007; 20:221-226.